MLLCF (Molecular Partners AG) Float Percentage Of Total Shares Outstanding: 57.74% (As of Jun. 27, 2026)


MLLCF Molecular Partners AG MLLCF
25 GF Score
Price $3.60
GF Value $0.42
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Molecular Partners AG Float Percentage Of Total Shares Outstanding?

Molecular Partners AG MLLCF 25 Float Percentage Of Total Shares Outstanding is 57.74% as of Jun. 27, 2026. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.42 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Molecular Partners AG's float shares is 21.66 Mil. Molecular Partners AG's total shares outstanding is 37.51 Mil. Molecular Partners AG's float percentage of total shares outstanding is 57.74%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Molecular Partners AG's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Molecular Partners AG's Institutional Ownership is 0.03%.

MLLCF
25GF Score
Molecular Partners AG MLLCF
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Molecular Partners AG Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Molecular Partners AG's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=21.66/37.51
=57.74%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 57.74% mean?
Molecular Partners AG (MLLCF) has a Float Percentage Of Total Shares Outstanding of 57.74% as of Jun. 27, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Molecular Partners AG and its competitors.
Is Molecular Partners AG's Float Percentage Of Total Shares Outstanding too high?
Molecular Partners AG's current Float Percentage Of Total Shares Outstanding is 57.74%. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Float Percentage Of Total Shares Outstanding compare to VRTX and REGN?
Molecular Partners AG's Float Percentage Of Total Shares Outstanding of 57.74% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Molecular Partners AG and its competitors. Molecular Partners AG's current Float Percentage Of Total Shares Outstanding is 57.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.42, compared to a current price of $3.60 — trading 757.1% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 57.74%. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Float Percentage Of Total Shares Outstanding is 57.74% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Molecular Partners AG (MLLCF) Overvalued in 2026?

Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued. The current stock price of $3.60 is trading 757.1% above its estimated GF Value™ of $0.42. GuruFocus considers Molecular Partners AG to be Significantly Overvalued.

Key valuation signals for MLLCF:

  • Float Percentage Of Total Shares Outstanding: 57.74%
  • GF Value™: $0.42 vs. price of $3.60 (757.1% above fair value)
  • GF Score™: 25/100 with 3 warning signs

No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Molecular Partners AG Business Description

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score

Get the complete analysis for MLLCF

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.60
Price
$0.42
GF Value